來凱醫藥-B(02105.HK)公佈年度業績 正推進開發多種創新候選藥物
格隆匯3月24日丨來凱醫藥-B(02105.HK)公告，公司其他收入由2023年的人民幣16.7百萬元增加人民幣21.5百萬元或128.7%，至2024年的人民幣38.2百萬元，主要是由於2024年銀行存款利息收入增加。年內虧損2.54億元，上年同期虧損3.69億元。
LAE102是公司自主研發針對ActRIIA的單克隆抗體。阻斷Activin-ActRII通路可促進肌肉再生和減少脂肪，這使LAE102成爲實現優質體重控制的潛力候選藥物。LAE103是ActRIIB選擇性抗體，LAE123是針對ActRIIA/IIB雙靶點抑制劑。兩者均爲公司產品管線中自主研發用於肌肉及其他疾病的抗體。集團已建立全面ActRII產品組合，致力最大化靶向ActRII受體的開發價值。
公司正推進開發多種創新候選藥物，包括小分子藥物、雙特異性抗體及雙功能NK銜接劑。公司致力推進管線以應對醫療需求未獲滿足的患者羣體，並計劃每年有一種候選藥物進入臨牀階段。
集團亦將繼續積極探索管線產品當中，與現有獲批藥物及傳統療法之間的潛在聯合治療機會。公司的LAE002(afuresertib)與氟維司羣的聯合試驗對接受前線標準內分泌╱抗雌激素療法（包括CDK4/6抑制劑）治療失敗的HR+/HER2-乳腺癌患者具有極大的臨牀價值，這是一項尚未滿足的醫療需求，具有巨大的市場潛力。公司的LAE002(afuresertib)聯合LAE001治療第二代A/AR耐藥性mCRPC亦爲mCRPC患者帶來了良好的治療效益。公司致力釋放候選藥物的臨牀價值。
於報告期內，集團已與禮來訂立臨牀合作協議，以支持及加速LAE102用於治療肥胖症的全球臨牀開發。公司計劃與更多全球領先藥企建立戰略合作夥伴關係，加速候選藥物資產的臨牀開發及商業化進程。公司將持續推進並擴展研發管線，矢志爲全球更多患者帶來改變生活的治療方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
